GP develops new antimicrobials to eliminate antibiotic-resistant bacteria. GP has established a platform for launching antimicrobials for human use and for use in livestock production.
Our core competency is the precise engineering of advanced probiotics. We use advanced bioengineering techniques to tailor performance probiotics that effectively target pathogens.
Our first line of products will help chicken producers produce healthy birds and distribute whole chickens and chicken parts that are not contaminated with salmonella, clostridia or campylobacter.
Our next line of products will help clinicians treat patients infected with antibiotic-resistant enterococci, clostridia and E. coli.